Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Danaher Corporation (DHR) vs Novartis AG (NVS) Price & Performance

Danaher CorporationTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Danaher Corporation vs Novartis AG — how do they compare? Danaher Corporation trades at $206.12 (market cap $145.83B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 2× Danaher Corporation's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.

DHRNVS
Market Cap
$145.83B$295.37B
Sector
HealthHealth
52-Week High
$242.05$168.62
52-Week Low
$161.91$119.31
Enterprise Value
$168.04B$336.69B
Dividend Yield
0.77%3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Danaher Corporation

Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.

The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.

Novartis AG

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Danaher Corporation

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.

Read more on DHR

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS